SAT0439 Integrated Safety Summary of Tofacitinib in Psoriatic Arthritis Clinical Studies

doi 10.1136/annrheumdis-2017-eular.1573
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis Across Phase III and Long-Term Extension Studies With Comparison to Real-World Observational Data

Drug Safety
ToxicologyPharmacology
2020English

Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis

Expert Review of Clinical Immunology
AllergyImmunology
2018English

Clinical Assessment in Psoriatic Arthritis

Reumatismo
Rheumatology
2011English

P067 Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritisand Psoriatic Arthritis

2019English

Clinical Heterogeneity of Early Psoriatic Arthritis

Modern Rheumatology Journal
2016English

AB0794 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Studies

2017English

P133 Clinical and Immunological Effects of Tofacitinib Therapy in Rheumatoid Arthritis

2019English

GRAPPA-OMERACT Initiative to Standardise Outcomes in Psoriatic Arthritis Clinical Trials and Longitudinal Observational Studies

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2017English

Psoriatic Arthritis

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy